{"entity":{"id":"gq1005","kind":"drug","name":"GQ1005","aka":[],"tldr":"GQ1005 is an experimental antibody-drug conjugate from GeneQuantum Healthcare (Suzhou) in phase 3 trials for HER2-positive breast cancer, aimed at HER2.","summary":"GQ1005 is an antibody-drug conjugate developed by GeneQuantum Healthcare (Suzhou). Its target is HER2 (the sponsor names HER2). The sponsor states: A HER2-targeting antibody-drug conjugate using a cleavable open-ring linker and a Topoisomerase I inhibitor payload. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07673029 (A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer), in HER2-positive breast cancer. The largest, NCT07673029, plans to enrol 228 participants with primary completion expected 2027-01-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of GQ1005","url":"https://clinicaltrials.gov/search?intr=GQ1005"},{"label":"Sponsor page","url":"https://www.genequantum.com/pipeline"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":["genequantum-healthcare-suzhou"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07673029"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"A HER2-targeting antibody-drug conjugate using a cleavable open-ring linker and a Topoisomerase I inhibitor payload.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gq1005/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","route":"/companies/genequantum-healthcare-suzhou/"}],"trial":[{"id":"nct07673029","kind":"trial","name":"A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07673029/"}]}}